{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:27:03Z","timestamp":1777634823790,"version":"3.51.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertension is a common and serious medical condition affecting millions of people worldwide. While existing treatments are effective for many hypertensive patients, up to one-third fail to achieve adequate blood pressure control\u2014often due to poor adherence, complex polypharmacy, or true pharmacological resistance. In this context, novel precision medicine approaches such as RNA-targeted therapeutics may represent tailored, long-acting alternatives particularly beneficial for patients with resistant hypertension, poor compliance, or multiple comorbidities. Small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) have shown promising results as potential treatments for hypertension. On the one hand, zilebesiran (formerly ALN-AGT01) is currently in phase 2 clinical trials and targets the hepatic synthesis of angiotensinogen through a novel mechanism of action. On the other hand, IONIS-AGT-LRX is a hepatocyte-directed antisense oligonucleotide designed to target AGT mRNA in hepatocytes, thereby reducing angiotensinogen synthesis and circulating plasma levels. Furthermore, literature show sparse trials on RNA-targeted nucleic acid therapeutics as potential hypertension treatment, in preclinical and clinical phases, in animal and human targets, analyzed in this review in their safety and efficacy. RNA-based drugs, administered as subcutaneous injections, offer several advantages over traditional antihypertensive agents, including greater target specificity and prolonged duration of action, potentially improving adherence and long-term blood pressure control. However, these therapies are not suitable for the acute management of hypertensive emergencies or urgencies, and evidence regarding their effects on cardiovascular outcomes, target organ protection, and mortality is still lacking. Further studies are warranted to define their role in clinical practice.<\/jats:p>","DOI":"10.1093\/ehjqcco\/qcaf127","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:32:00Z","timestamp":1760959920000},"page":"358-365","source":"Crossref","is-referenced-by-count":2,"title":["RNA-targeted therapeutics in arterial hypertension"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-5467","authenticated-orcid":false,"given":"Egidio","family":"Imbalzano","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina , Messina 98122, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-8529","authenticated-orcid":false,"given":"Riccardo M","family":"Inciardi","sequence":"additional","affiliation":[{"name":"ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia 25123, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana","family":"Orlando","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina , Messina 98122, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Amati","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Bari , Bari ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-6836","authenticated-orcid":false,"given":"Flavio","family":"D\u2019Ascenzi","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, Division of Cardiology, University of Siena , Siena ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Liga","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa , Pisa ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Vittoria","family":"Mattioli","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia , Modena 41125 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna Gigliotti","family":"De Fazio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina , Messina 98122, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concetta","family":"Pastore","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, Division of Cardiology, University of Siena , Siena ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital , IRCCS, Bologna ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-0053","authenticated-orcid":false,"given":"Pietro","family":"Scicchitano","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital \u2018F. Perinei\u2019 , Altamura (BA) ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Cameli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Bari , Bari ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2026042901114453000_qcaf127-B1","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026042901114453000_qcaf127-B2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","article-title":"Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants","volume":"389","author":"Zhou","year":"2017","journal-title":"Lancet"},{"key":"2026042901114453000_qcaf127-B3","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"2026042901114453000_qcaf127-B4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.phrs.2017.11.003","article-title":"Hypertension and cardiovascular risk: general aspects","volume":"129","author":"Kjeldsen","year":"2018","journal-title":"Pharmacol Res"},{"key":"2026042901114453000_qcaf127-B5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/HJH.0000000000000112","article-title":"Hypertension, inflammation and atrial fibrillation","volume":"32","author":"Angeli","year":"2014","journal-title":"J Hypertens"},{"key":"2026042901114453000_qcaf127-B6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","article-title":"Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies","volume":"122","author":"Verdecchia","year":"2018","journal-title":"Circ Res"},{"key":"2026042901114453000_qcaf127-B7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fcvm.2020.00005","article-title":"Hypertension and the risk of dementia","volume":"7","author":"Sierra","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2026042901114453000_qcaf127-B8","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment, and control of hypertension, 1988\u20132008","volume":"303","author":"Egan","year":"2010","journal-title":"JAMA"},{"key":"2026042901114453000_qcaf127-B9","first-page":"66","article-title":"The effect of medical technology innovations on patient outcomes, 1990\u20132015: results of a physician survey","volume":"25","author":"Wamble","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2026042901114453000_qcaf127-B10","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/HYPERTENSIONAHA.122.19430","article-title":"Novel pharmacological approaches in the treatment of hypertension: a focus on RNA-based therapeutics","volume":"80","author":"Addison","year":"2023","journal-title":"Hypertension"},{"key":"2026042901114453000_qcaf127-B11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"2026042901114453000_qcaf127-B12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40291-019-00434-w","article-title":"Leading RNA interference therapeutics part 1: silencing hereditary transthyretin amyloidosis, with a focus on patisiran","volume":"24","author":"Titze-de-Almeida","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"2026042901114453000_qcaf127-B13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/MNH.0000000000000586","article-title":"Targeting angiotensinogen with RNA-based therapeutics","volume":"29","author":"Ren","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026042901114453000_qcaf127-B14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/ph15050575","article-title":"Biotechnological evolution of siRNA molecules: from bench tool to the refined drug","volume":"15","author":"de Brito e Cunha","year":"2022","journal-title":"Pharmaceuticals"},{"key":"2026042901114453000_qcaf127-B15","doi-asserted-by":"crossref","first-page":"e027694","DOI":"10.1161\/JAHA.122.027694","article-title":"Small interfering RNA therapeutics in hypertension: a viewpoint on vasopressor and vasopressor-sparing strategies for counteracting blood pressure lowering by angiotensinogen-targeting small interfering RNA","volume":"11","author":"Ranasinghe","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026042901114453000_qcaf127-B16","doi-asserted-by":"crossref","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"2026042901114453000_qcaf127-B17","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.bmcl.2004.07.018","article-title":"Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells","volume":"14","author":"Lorenz","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"2026042901114453000_qcaf127-B18","doi-asserted-by":"crossref","first-page":"e240728","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"2026042901114453000_qcaf127-B19","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2026042901114453000_qcaf127-B20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med"},{"key":"2026042901114453000_qcaf127-B21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/molecules27020536","article-title":"Small drugs, huge impact: the extraordinary impact of antisense oligonucleotides in research and drug development","volume":"27","author":"Quemener","year":"2022","journal-title":"Molecules"},{"key":"2026042901114453000_qcaf127-B22","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"2026042901114453000_qcaf127-B23","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1021\/acs.jmedchem.5b01948","article-title":"Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes","volume":"59","author":"Prakash","year":"2016","journal-title":"J Med Chem"},{"key":"2026042901114453000_qcaf127-B24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3389\/fphys.2018.00953","article-title":"RNA therapeutics in cardiovascular precision medicine","volume":"9","author":"Laina","year":"2018","journal-title":"Front Physiol"},{"key":"2026042901114453000_qcaf127-B25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacbts.2021.04.004","article-title":"Antisense inhibition of angiotensinogen with IONIS-AGT-LRx: results of phase 1 and phase 2 studies","volume":"6","author":"Morgan","year":"2021  3","journal-title":"JACC Basic Transl Sci"},{"key":"2026042901114453000_qcaf127-B26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11906-020-01070-0","article-title":"Hypertension during pregnancy","volume":"22","author":"Agrawal","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"2026042901114453000_qcaf127-B27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/01.HYP.0000257797.49289.71","article-title":"Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia","volume":"49","author":"Herse","year":"2007","journal-title":"Hypertension"},{"key":"2026042901114453000_qcaf127-B28","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1172\/JCI99417","article-title":"RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models","volume":"130","author":"Haase","year":"2020","journal-title":"J Clin Invest"},{"key":"2026042901114453000_qcaf127-B29","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"2026042901114453000_qcaf127-B30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1074248416676392","article-title":"Phospholamban inhibition by a single dose of locked nucleic acid antisense oligonucleotide improves cardiac contractility in pressure overload-induced systolic dysfunction in mice","volume":"22","author":"Morihara","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026042901114453000_qcaf127-B31","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","article-title":"Hypertension as cardiovascular risk factor in chronic kidney disease","volume":"132","author":"Burnier","year":"2023","journal-title":"Circ Res"},{"key":"2026042901114453000_qcaf127-B32","doi-asserted-by":"crossref","first-page":"9392","DOI":"10.1074\/jbc.M006889200","article-title":"Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation","volume":"276","author":"Sato","year":"2001","journal-title":"J Biol Chem"},{"key":"2026042901114453000_qcaf127-B33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1524-6175.2005.04648.x","article-title":"Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far","volume":"8","author":"Weir","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026042901114453000_qcaf127-B34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pharmthera.2005.09.002","article-title":"Mechanisms of target organ damage caused by hypertension: therapeutic potential","volume":"111","author":"Cohuet","year":"2006","journal-title":"Pharmacol Ther"},{"key":"2026042901114453000_qcaf127-B35","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41440-022-00949-6","article-title":"Prognostic value of target organ damage in patients with cardiovascular risks","volume":"45","author":"Nakagawa","year":"2022","journal-title":"Hypertens Res"},{"key":"2026042901114453000_qcaf127-B36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.36290\/vnl.2023.017","article-title":"The impact of uncontrolled hypertension on the CNS","volume":"69","author":"Tomek","year":"2023","journal-title":"Vnitr Lek"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcaf127\/64843942\/qcaf127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/3\/358\/64843942\/qcaf127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/3\/358\/64843942\/qcaf127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:16:57Z","timestamp":1777439817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/12\/3\/358\/8296659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2026,4,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcaf127","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,10,22]]}}}